학술논문

CRISPR–Cas9 screens in human cells and primary neurons identify modifiers of C9ORF72 dipeptide-repeat-protein toxicity
Document Type
article
Source
Nature Genetics. 50(4)
Subject
Biochemistry and Cell Biology
Biological Sciences
Brain Disorders
Rare Diseases
Human Genome
Genetics
Frontotemporal Dementia (FTD)
Biotechnology
ALS
Dementia
Acquired Cognitive Impairment
Stem Cell Research
Neurodegenerative
Neurosciences
2.1 Biological and endogenous factors
Aetiology
Neurological
Active Transport
Cell Nucleus
Amyotrophic Lateral Sclerosis
Animals
C9orf72 Protein
CRISPR-Cas Systems
DNA Repeat Expansion
Endoplasmic Reticulum Stress
Frontotemporal Dementia
Gene Knockout Techniques
HeLa Cells
Humans
K562 Cells
Membrane Proteins
Mice
Microsatellite Repeats
Motor Neurons
Thioredoxins
rab GTP-Binding Proteins
rab7 GTP-Binding Proteins
Hela Cells
Medical and Health Sciences
Developmental Biology
Agricultural biotechnology
Bioinformatics and computational biology
Language
Abstract
Hexanucleotide-repeat expansions in the C9ORF72 gene are the most common cause of amyotrophic lateral sclerosis and frontotemporal dementia (c9ALS/FTD). The nucleotide-repeat expansions are translated into dipeptide-repeat (DPR) proteins, which are aggregation prone and may contribute to neurodegeneration. We used the CRISPR-Cas9 system to perform genome-wide gene-knockout screens for suppressors and enhancers of C9ORF72 DPR toxicity in human cells. We validated hits by performing secondary CRISPR-Cas9 screens in primary mouse neurons. We uncovered potent modifiers of DPR toxicity whose gene products function in nucleocytoplasmic transport, the endoplasmic reticulum (ER), proteasome, RNA-processing pathways, and chromatin modification. One modifier, TMX2, modulated the ER-stress signature elicited by C9ORF72 DPRs in neurons and improved survival of human induced motor neurons from patients with C9ORF72 ALS. Together, our results demonstrate the promise of CRISPR-Cas9 screens in defining mechanisms of neurodegenerative diseases.